Litcius/Paper detail

Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms

Kai Liu, Xing Zhao, Xue Qi, Dongliang Hou, Hao-Bin Li, Yuhao Gu, Qing‐Long Xu

2021European Journal of Medicinal Chemistry20 citationsDOIOpen Access PDF

Topics & Concepts

Peroxisome proliferator-activated receptorAgonistPPAR agonistRosiglitazonePharmacologyChemistryNuclear receptorDiabetes mellitusReceptorPioglitazonePeroxisomeInternal medicineEndocrinologyType 2 diabetesMedicineTranscription factorBiochemistryGenePeroxisome Proliferator-Activated ReceptorsChronic Kidney Disease and DiabetesImmune cells in cancer
Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms | Litcius